Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Snape

Showing results (1-10 of 169) with videos related to

Pageof 17
Sort By:
The Lancet. Global Health|February 15, 2017
Persistence of immune responses induced by Ebola virus vaccinesMatthew D Snape
The Lancet. Public Health|December 19, 2017
Where next? The emergence of hypervirulent W meningococcus in the NetherlandsJonathan Broad, Matthew D Snape
Lancet (London, England)|August 6, 2013
The price of prevention: what now for immunisation against meningococcus B?Richard Moxon, Matthew D Snape
Expert Review of Vaccines|January 24, 2014
Will booster doses be required for serogroup B meningococcal vaccine?Fiona McQuaid, Matthew D Snape
Archives of Disease in Childhood|December 2, 2010
Immunisation of adolescents in the UKAshutosh R Kale, Matthew D Snape
The Lancet. Infectious Diseases|December 29, 2004
Meningococcal polysaccharide-protein conjugate vaccinesMatthew D Snape, Andrew J Pollard
Lancet (London, England)|May 31, 2011
Fine with five? Shorter antibiotic courses for childhood meningitisMatthew D Snape, Dominic F Kelly
Expert Review of Vaccines|August 30, 2013
A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?Natalie G Martin, Matthew D Snape
Science (New York, N.Y.)|September 22, 2020
COVID-19 in children and young peopleMatthew D Snape, Russell M Viner
Expert Review of Vaccines|May 25, 2011
A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal diseaseEe Lyn Su, Matthew D Snape
Pageof 17

Showing results (1-10 of 169) with videos related to

Sort By:
Pageof 17
The Lancet. Global Health|February 15, 2017
Persistence of immune responses induced by Ebola virus vaccinesMatthew D Snape
The Lancet. Public Health|December 19, 2017
Where next? The emergence of hypervirulent W meningococcus in the NetherlandsJonathan Broad, Matthew D Snape
Lancet (London, England)|August 6, 2013
The price of prevention: what now for immunisation against meningococcus B?Richard Moxon, Matthew D Snape
Expert Review of Vaccines|January 24, 2014
Will booster doses be required for serogroup B meningococcal vaccine?Fiona McQuaid, Matthew D Snape
Archives of Disease in Childhood|December 2, 2010
Immunisation of adolescents in the UKAshutosh R Kale, Matthew D Snape
The Lancet. Infectious Diseases|December 29, 2004
Meningococcal polysaccharide-protein conjugate vaccinesMatthew D Snape, Andrew J Pollard
Lancet (London, England)|May 31, 2011
Fine with five? Shorter antibiotic courses for childhood meningitisMatthew D Snape, Dominic F Kelly
Expert Review of Vaccines|August 30, 2013
A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?Natalie G Martin, Matthew D Snape
Science (New York, N.Y.)|September 22, 2020
COVID-19 in children and young peopleMatthew D Snape, Russell M Viner
Expert Review of Vaccines|May 25, 2011
A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal diseaseEe Lyn Su, Matthew D Snape
Pageof 17